Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $13.00 at SunTrust Banks

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price hoisted by analysts at SunTrust Banks from $9.00 to $13.00 in a research note issued on Thursday, BenzingaRatingsTable reports. The firm presently has a “hold” rating on the stock. SunTrust Banks’ price target points to a potential upside of 1.06% from the stock’s current price.

A number of other research firms also recently weighed in on TEVA. Cfra upped their price target on shares of Teva Pharmaceutical Industries from $11.00 to $13.00 and gave the stock a “hold” rating in a research note on Wednesday. ValuEngine downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald upped their price target on shares of Teva Pharmaceutical Industries from $9.00 to $15.00 and gave the stock a “neutral” rating in a research note on Wednesday. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $8.00 target price on the stock in a research report on Tuesday, November 12th. Finally, Gabelli raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, October 16th. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $11.29.

Shares of NYSE TEVA traded down $0.59 during mid-day trading on Thursday, reaching $12.86. The company had a trading volume of 13,452,995 shares, compared to its average volume of 18,127,916. Teva Pharmaceutical Industries has a twelve month low of $6.07 and a twelve month high of $19.21. The company has a debt-to-equity ratio of 1.62, a quick ratio of 0.56 and a current ratio of 0.89. The stock has a market capitalization of $13.49 billion, a PE ratio of -3.32, a price-to-earnings-growth ratio of 1.24 and a beta of 1.84. The stock’s 50 day moving average is $10.32 and its 200-day moving average is $8.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.61 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. The business had revenue of $4.47 billion for the quarter, compared to the consensus estimate of $4.35 billion. During the same period in the prior year, the business posted $0.53 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was up 1.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.27 EPS for the current year.

In related news, VP Hafrun Fridriksdottir sold 4,310 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.49, for a total value of $45,211.90. Following the completion of the sale, the vice president now owns 24,883 shares in the company, valued at $261,022.67. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Brendan P. O’grady sold 4,799 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $12.27, for a total transaction of $58,883.73. Following the completion of the sale, the executive vice president now owns 18,255 shares of the company’s stock, valued at approximately $223,988.85. The disclosure for this sale can be found here. Insiders have sold 21,647 shares of company stock valued at $257,561 over the last 90 days. Corporate insiders own 0.49% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. Menora Mivtachim Holdings LTD. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $82,369,000. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 184.5% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 12,721,214 shares of the company’s stock worth $124,668,000 after buying an additional 8,250,000 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $52,412,000. Phoenix Holdings Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $34,337,000. Finally, Commerzbank Aktiengesellschaft FI increased its holdings in shares of Teva Pharmaceutical Industries by 49.4% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 8,682,389 shares of the company’s stock worth $59,735,000 after buying an additional 2,869,139 shares in the last quarter. Institutional investors and hedge funds own 53.73% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: Growth Stocks

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.